REDHILL B.S.ADR 10/IL-,01 Forum: Community User: MeisterYoda1

Die skeptischste Analyse liegt bei 17 Dollar...

Ok, danke. Was denkt ihr, wo es jetzt hingeht?

Die Nachricht ist vom letzten Mittwoch, noch vor der Q1-Präsentation...

Für die gute Nachricht, tut sich aber relativ wenig...

Guten Morgen, https://www.finanznachrichten.de/nachrichten-2021-05/53015470-redhill-biopharma-erhaelt-notice-of-allowance-zur-einreichung-der-patentanmeldungen-fuer-opganib-und-rhb-107-zur-behandlung-von-covid-19-in-den-usa-007.htm

Sieht doch erstmal ganz gut aus 👍, schönes Wochenende gewünscht

Soooo....jetzt aber Vollgas🤣

https://finance.yahoo.com/news/35-best-ideas-companies-present-231500576.html

https://www.selectscience.net/industry-news/redhill-biopharma-has-received-allowances-for-us-patent-applications-covering-opaganib-and-rhb-107-for-covid-19/?artID=54798

Moin zusammen, schaffen wir heute die 6 €???

Thx Quincy....das Forum kannte ich bei WO noch garnicht 👍

Gehe mal ins WO Forum da findest du die Zahlen

Hat jemand eine Zusammenfassung der Zahlen? Wann können wir Bewegung erwarten?

Gleich Webcast http://ir.redhillbio.com/events

RedHill Biopharma (NASDAQ: RDHL) today reported its financial results and operational highlights for the first quarter ended March 31, 2021. · Q1/2021 net revenues of approximately $20.6 million compared to $1.1 million for Q1/2020; Cash balance of approximately $92 million as of March 31, 2021, compared to approximately $115 million as of March 31, 2020 · Talicia® prescription volume grew 11% versus previous quarter; Movantik® new prescriptions in the first quarter 4% higher than Q1/2020 · Opaganib global Phase 2/3 study almost 100% enrolled · Management to host webcast today, at 8:30 a.m. EST Dror Ben-Asher, RedHill’s Chief Executive Officer, said: “The progress of our two novel, oral COVID-19 programs has put RedHill at the forefront of oral COVID-19 therapeutics development. Opaganib, one of the most advanced and promising novel, dual-mode of action, oral drug candidates in development for COVID-19, now has almost 100% enrollment in its global 464-patient Phase 2/3 study in severe COVID-19.” Mr. Ben-Asher continued: “Commercially, a strong end to the first quarter has set up 2021 for growth, reversing a slow start to the year across the industry. Movantik’s new prescriptions in the first quarter outperformed the same quarter last year, while Talicia’s growth in prescription volume, repeat prescribing and new prescribers will be key growth drivers going forward. With the U.S. now emerging from the shadows of COVID-19, patients returning to clinics and travel resuming, positively affecting Aemcolo’s prospects, we are excited for the promise 2021 holds.” Micha Ben Chorin, Chief Financial Officer at RedHill, added: “A strong March helped rebalance quarterly revenues, as we maintained cash burn rate at previous quarter levels. With a healthy balance sheet, we are well-positioned to drive our late-stage R&D programs forward, as we work diligently to build on the upward trends across our core business.”